Janney Montgomery Scott LLC Acquires Shares of 75,318 MeiraGTx Holdings plc (NASDAQ:MGTX)

Janney Montgomery Scott LLC acquired a new stake in shares of MeiraGTx Holdings plc (NASDAQ:MGTX) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 75,318 shares of the company’s stock, valued at approximately $459,000. Janney Montgomery Scott LLC owned 0.10% of MeiraGTx at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. SG Americas Securities LLC raised its holdings in shares of MeiraGTx by 13.3% in the fourth quarter. SG Americas Securities LLC now owns 22,240 shares of the company’s stock worth $135,000 after buying an additional 2,617 shares during the period. The Manufacturers Life Insurance Company raised its holdings in shares of MeiraGTx by 19.0% in the second quarter. The Manufacturers Life Insurance Company now owns 17,763 shares of the company’s stock worth $75,000 after buying an additional 2,839 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of MeiraGTx by 1.2% in the third quarter. JPMorgan Chase & Co. now owns 342,667 shares of the company’s stock worth $1,429,000 after buying an additional 4,186 shares during the period. State Street Corp raised its holdings in shares of MeiraGTx by 0.9% in the third quarter. State Street Corp now owns 574,727 shares of the company’s stock worth $2,397,000 after buying an additional 5,251 shares during the period. Finally, BNP Paribas Financial Markets raised its holdings in shares of MeiraGTx by 142.5% in the third quarter. BNP Paribas Financial Markets now owns 9,319 shares of the company’s stock worth $39,000 after buying an additional 5,476 shares during the period. 67.48% of the stock is currently owned by hedge funds and other institutional investors.

MeiraGTx Trading Down 2.0 %

MGTX opened at $6.81 on Monday. The stock’s fifty day moving average is $6.22 and its two-hundred day moving average is $5.42. The company has a market capitalization of $532.20 million, a P/E ratio of -5.63, a PEG ratio of 0.38 and a beta of 1.25. MeiraGTx Holdings plc has a 52 week low of $3.85 and a 52 week high of $7.37. The company has a quick ratio of 2.34, a current ratio of 2.34 and a debt-to-equity ratio of 0.86.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Royal Bank of Canada increased their price target on MeiraGTx from $9.00 to $11.00 and gave the stock an “outperform” rating in a report on Thursday, November 14th. Chardan Capital reiterated a “buy” rating and issued a $36.00 price target on shares of MeiraGTx in a report on Monday, November 18th.

Insiders Place Their Bets

In other MeiraGTx news, CFO Richard Giroux sold 24,000 shares of the firm’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $6.29, for a total transaction of $150,960.00. Following the transaction, the chief financial officer now directly owns 849,947 shares in the company, valued at $5,346,166.63. This trade represents a 2.75 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Alexandria Forbes sold 35,839 shares of the firm’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $6.47, for a total value of $231,878.33. Following the transaction, the chief executive officer now owns 1,395,102 shares in the company, valued at $9,026,309.94. The trade was a 2.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 8.40% of the stock is currently owned by company insiders.

About MeiraGTx

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia.